From the Journals

What Drives Progression Despite TNFi?

Study shows complement activation marker C3dg, MASP-1, and MASP-3 levels before tumor necrosis factor inhibitor therapy predicted new bone formation after 2 years of follow-up among axial spondyloarthritis patients with a high risk of radiographic progression.

Share

5 Key Takeaways

  • 1

    Study published in RMD Open focused on axSpA and complement system.

  • 2

    96 patients undergoing TNFi therapy were analyzed.

  • 3

    Baseline levels of C3dg and MASP-1 linked to new bone formation.

  • 4

    20% of patients showed new bone formation despite treatment response.

  • 5

    High levels of complement proteins are associated with radiographic progression.

Original Source(s)

What Drives Progression Despite TNFi?

Study shows complement activation marker C3dg, MASP-1, and MASP-3 levels before tumor necrosis factor inhibitor therapy predicted new bone formation after 2 years of follow-up among axial spondyloarthritis patients with a high risk of radiographic progression.

  • by Julie Greenbaum

  • December 11, 2025

  • 2 min

Related Content

How Safe Are FDA-Cleared AI Tools?

“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."